Latest news about Genmed:
1. Additional marketing authorisations
Genmed is glad to announce that six additional MA’s (marketing authorisations) for Paracetamol 500mg have been granted for European countries in Central and Eastern Europe. Czech Republic, Slovakia and Poland, along with the three Baltic States are important emerging markets for generic medicines. “We can now finalise our negotiations with market leading retailers in these important new markets, declares CEO Erwin Bouwens, “and start production in the coming quarter”. Genmed expects to report on definitive orders this July.
2. Distribution Agreement Dr. Max Pharma
Genmed has entered the Czech and Slovakian Markets. It has reached a long-term distribution contract with Dr Max Pharma. Dr. Max is one of the biggest pharmacy chains in Central Europe. It is a market leader in the Czech Republic (20% market share) and Slovakia (15%).
About Dr Max (from www.pentainvestments.com)
• Over 500 pharmacies in the chain
• Over 130,000 customers served daily
• Over 3,000 employees
Genmed will provide Paracetamol 500mg tablets for Dr Max’ new private label. Genmed and Dr Max are currently discussing the final logistic issues. The first shipment is expected the coming month. Genmed is looking forward to a long and successful partnership.
3. Poland
Genmed has entered the Polish market and has started preparation for production for the Dr Max Brand in Poland. “We are delighted to enter this large European market”, CEO Erwin Bouwens declares” A Promising market to which many leading brands have no access”. With this relatively low competition and our prime quality Paracetamol, Genmed expects to produce growing amounts for the Polish Pharmacy market in the coming years”.
